Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Joan M, Robbins"'
Autor:
Kader Yagiz, Maria E. Rodriguez-Aguirre, Fernando Lopez Espinoza, Tiffany T. Montellano, Daniel Mendoza, Leah A. Mitchell, Carlos E. Ibanez, Noriyuki Kasahara, Harry E. Gruber, Douglas J. Jolly, Joan M. Robbins
Publikováno v:
Molecular Therapy: Oncolytics, Vol 8, Iss , Pp 14-26 (2018)
Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemi
Externí odkaz:
https://doaj.org/article/6ac8a40fe95149c799cb30f64a45ae08
Autor:
Leah Mitchell, Akihito Inagaki, Harry E. Gruber, Kei Hiraoka, Fernando Lopez Espinoza, Noriyuki Kasahara, Joan M. Robbins, Douglas J. Jolly, Daniel Mendoza, Yuki Kato
Publikováno v:
Neuro-Oncology
Neuro-oncology, vol 19, iss 7
Neuro-oncology, vol 19, iss 7
Author(s): Mitchell, Leah A; Lopez Espinoza, Fernando; Mendoza, Daniel; Kato, Yuki; Inagaki, Akihito; Hiraoka, Kei; Kasahara, Noriyuki; Gruber, Harry E; Jolly, Douglas J; Robbins, Joan M | Abstract: BackgroundToca 511 (vocimagene amiretrorepvec) is a
Autor:
Christopher R. Logg, Joan M. Robbins, Douglas J. Jolly, Carlos E. Ibanez, Harry E. Gruber, Kathrina Cunanan, Cynthia Burrascano, Yanzheng Liu, Noriyuki Kasahara, Amy H. Lin
Publikováno v:
Human Gene Therapy Methods. 27:59-70
We have developed retroviral replicating vectors (RRV) derived from Moloney murine gammaretrovirus with an amphotropic envelope and an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES)-transgene cassette downstream of the env gene
Publikováno v:
Cancer Research. 80:6713-6713
A series of investigational oncolytic immunotherapies based on DNX-2401 (tasadenoturev) are under development for the treatment of advanced cancers. Viruses “armed” with cell surface or secreted immune modulatory molecules inserted in the DNX-240
Autor:
Bryan Martin, Joan M. Robbins, Fernando Lopez Espinoza, Douglas J. Jolly, Harry E. Gruber, Daniel Pertschuk, Noriyuki Kasahara, Shraddha Parab, Carlos E. Ibanez, Tiffany T. Huang, Oscar Diago, Derek Ostertag, Ryan Burnett, Florence M. Hofman
Publikováno v:
Human gene therapy, vol 26, iss 2
Toca 511 (vocimagene amiretrorepvec), a nonlytic, amphotropic retroviral replicating vector (RRV), encodes and delivers a functionally optimized yeast cytosine deaminase (CD) gene to tumors. In orthotopic glioma models treated with Toca 511 and 5-flu
Autor:
Joan M. Robbins, Douglas J. Jolly, Leah Mitchell, Yuki Kato, Tiffany T. Huang, Masamichi Takahashi, Derek Ostertag, Katrin Hacke, Hiroshi Matsumoto, Carol A. Kruse, Harry E. Gruber, Shuichi Kamijima, Noriyuki Kasahara, Akihito Inagaki, Kei Hiraoka
Publikováno v:
Neuro-Oncology
Neuro-oncology, vol 19, iss 7
Neuro-oncology, vol 19, iss 7
Author(s): Hiraoka, Kei; Inagaki, Akihito; Kato, Yuki; Huang, Tiffany T; Mitchell, Leah A; Kamijima, Shuichi; Takahashi, Masamichi; Matsumoto, Hiroshi; Hacke, Katrin; Kruse, Carol A; Ostertag, Derek; Robbins, Joan M; Gruber, Harry E; Jolly, Douglas J
Autor:
Carlos E. Ibanez, John Forsayeth, Krystof S. Bankiewicz, Joan M. Robbins, Douglas J. Jolly, Adrian P. Kells, Noriyuki Kasahara, Yuying Zhai, Dali Yin, Harry E. Gruber
Publikováno v:
Cancer gene therapy
In the present study, we compared the therapeutic effect of tumor-selective retroviral replicating vectors (RRV) expressing the yeast cytosine deaminase (CD) delivered by convection-enhanced delivery (CED) or simple injection, followed by systemic ad
Autor:
Alice Chu, Oscar Diago, Santosh Kesari, Derek Ostertag, Michelle M. Hanna, Leah Mitchell, Timothy F. Cloughesy, Joan M. Robbins, Steven N. Kalkanis, Douglas J. Jolly, David Piccioni, J. Bradley Elder, Asha Das, Phioanh L. Nghiemphu, Albert Lai, David McCarthy, Harry E. Gruber, Clark C. Chen, Maria Rodriguez-Aguirre, Michael A. Vogelbaum, Stephen Bloomfield, Dawn Gammon, Daniel J. Hogan, Joseph Landolfi, Tom Mikkelsen, Bob S. Carter, Ian Lee, Tobias Walbert, Noriyuki Kasahara, Linda M. Liau
Publikováno v:
Science translational medicine, vol 8, iss 341
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the investigational prodrug Toca FC (extended-relea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d905a7c9b1b4e04dafeae3added4f8a
https://escholarship.org/uc/item/9925m6q0
https://escholarship.org/uc/item/9925m6q0
Autor:
Fernando Lopez Espinoza, Kader Yagiz, Joan M. Robbins, Douglas J. Jolly, Tiffany T. Huang, Carlos E. Ibanez, Daniel Mendoza, Harry E. Gruber
BACKGROUND Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, used in combination with 5-fluorocytosine (5-FC) kills tumor by local production of 5-fluorouracil (5-FU), inducing local and systemic immunotherapeutic response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e97a79f6bc1c8f702544c8233543615
https://europepmc.org/articles/PMC5035524/
https://europepmc.org/articles/PMC5035524/
Autor:
Alice Chu, Michael A. Vogelbaum, Carlos E. Ibanez, Steven N. Kalkanis, Harry E. Gruber, Derek Ostertag, Joan M. Robbins, Douglas J. Jolly, Andreas Niethammer, Kadir Yagiz, Oscar Diego, Timothy F. Cloughesy
Recurrent high grade glioma (HGG) remains resistant to standard therapies with survival ranging from 7.2-8.1 months. A Phase 1 clinical study using an investigational retroviral replicating vector (RRV), Toca 511, in combination with investigational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16aaf0a10e34f62e39f242a9ef396c04
https://europepmc.org/articles/PMC4638728/
https://europepmc.org/articles/PMC4638728/